Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 819 results for "eisai"

Eisai Pharma to introduce new drugs, says MD

Eisai Pharmaceuticals India Pvt Ltd, which has a unit in the Jawahar Pharma city in Visakhapatnam district, has taken up an expansion project and is also introducing new drugs to the Indian market, a...
 Business Line1 week ago

Eisai launches expansion of facility

Launch of new drugs for lung and thyroid cancer and epilepsy next year
 The Hindu1 week ago
Pharmaceutical Business Review

DRL in agreement with Eisai Co, Japan

Acquires rights to Investigational Anticancer Agent E7777 for US, Europe and certain emerging markets from Eisai Dr Reddy's Laboratories (DRL) has entered into a licensing agreement with Eisai Co, Japan by which DRL will be granted exclusive ...
 CPhI.cn1 month ago Dr. Reddy's in licensing agreement with Eisai  The Hindu1 month ago Dr Reddy's ties up with Eisai  The Telegraph1 month ago Dr. Reddy's Acquires Anticancer Drug Rights from Eisai  Yahoo! Singapore1 month ago
[x]  

EISAI : To support relief efforts for 2016 kumamoto earthquakes

Release date- 20042016 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') expresses its deepest sorrow for those who have lost their lives, and offers heartfelt sympathy to the victims of the earthquakes that recently struck Kumamoto ...
 4 Traders1 week ago Eisai Announces Non-Clinical Research Findings At AACR 107th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus  FirstWord Pharma2 weeks ago Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies  PharmaAsia2 weeks ago EISAI : Announces non-clinical research findings at aacr 107th annual meeting regarding combination of anticancer agent lenvatinib with everolimus  4 Traders2 weeks ago
[x]  

Morphotek's farletuzumab flunks late-stage trial in treatment-resistant ovarian cancer

A Phase 3 study, MORAb-003-004, assessing Eisai ( OTC:ESALF )( OTCPK:ESALY ) subsidiary Morphotek's farletuzumab, in combination with platinum-based chemo, in ovarian cancer patients who relapsed after chemo treatment failed to achieve its primary ...
 Seeking Alpha2 weeks ago Morphotek Announces Publication Of Phase 3 Results From MORAb-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients  WorldNetDaily2 weeks ago Clinical Development News, April 11-15  Dow Jones Financial Information Services2 weeks ago
[x]  

Eisai wins approval to use Aricept for DLB treatment in Philippines

HI-Eisai Pharmaceutical, a subsidiary of Eisai in the Philippines, has obtained approval for a new indication Aricept (donepezil hydrochloride) to treat dementia with Lewy bodies (DLB). DLB is a degenerative form of dementia discovered in Japan ...
 CPhI.cn2 weeks ago

Eisai partners with PharmStandard to localise production in Russia

Eisai has collaborated with Russian pharmaceutical company PharmStandard to localise production of its products in the country. As per the agreed terms, Eisai will produce its oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as ...
 CPhI.cn3 weeks ago Following recent visit to Japan, Tsongas tours Japanese pharmaceutical company in Andover  Congresswoman Niki Tsongas3 weeks ago Pharmstandard to produce drugs for Eisai in Russia  Pharma Letter3 weeks ago Eisai and PharmStandard sign co-operation agreements in Russia  Manufacturing Chemist4 weeks ago
[x]  
Monthly Prescribing Reference

FDA approves new formulation of Eisai's Fycompa to treat seizure disorders

The US Food and Drug Administration (FDA) has approved Eisai's Fycompa (perampanel) oral suspension as adjunctive therapy to treat partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic ...
 Pharmaceutical Business Review1 day ago FDA Okays Oral Formulation of Fycompa  RxList1 day ago New Formulation of Fycompa Approved for Seizure Disorders  Monthly Prescribing Reference2 days ago FDA Okays Oral Formulation of Perampanel (Fycompa)  Diabetes Care15 hours ago

BIAL and Eisai Announce New Data That Once-daily Zebinix® (eslicarbazepine acetate) Monotherapy is Effective and Well Tolerated According to First Data Presented at the American Academy of Neurology (AAN) Annual Meeting

_ Emerging Science Platform Session abstract presentation times: Tuesday 19 April 17:45 - 19:15 PDT PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR AUSTRIAN/SWISS/US JOURNALISTS Positive results from a Bial sponsored Phase III study[1],[2] in adult ...
 Sys-Con Media2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less